SUGAR LAND BUSINESS CELEBRATES FIVE YEARS & 130 BILLION STEM CELLS
– FOR IMMEDIATE RELEASE –
CONTACT: Jan Shultis | Phone: (281) 725-1272 | Email: firstname.lastname@example.org | Sugar Land, Texas
Sugar Land, Texas, 2 April 2021: Houston area stem cell banking company Hope Biosciences marks its five-year anniversary this month, celebrating 130 billion cultured mesenchymal stem cells and the myriad of ways those cells are benefitting clients.
Hope Biosciences occupies a unique position in the regenerative medicine space, noteworthy both for patented cell culture methods and for their devotion to getting cells to patients through robust collaboration with academic and clinical research organizations.
“All stem cells are not created equal, because how your stem cells are preserved, nourished, and grown influences whether you will be able to use them, when you need them,” explains Hope Biosciences CEO Donna Chang. “At Hope Biosciences we employ a series of patented processes to offer what we believe is the best solution for safe, secure stem cell banking on the market.”
Hope Biosciences was founded in 2016 by Donna Chang, who was formally joined a few days later by scientist Hyeonggeun Park, inventor of the technology used by Hope Bio. The company banks pure mesenchymal stem cells harvested from adult fat, or from the placenta when banking newborns. A proprietary process then allows stem cell culturists to generate more than 1,000 fresh doses of stem cell therapy for each client, exponentially more than any individual can be projected to use in a lifetime. The volume of cells is important because Hope Bio’s research shows that repeated treatments are needed over time to treat chronic disease or injury. Hope Bio’s technology also creates a five-day cell viability window, unprecedented in stem cell culturing. This window means that Hope Biosciences can ship stem cells, in turn creating the ability to literally serve the world.
“Our technology is cutting-edge, and there is a great deal of excitement outside of our organization for the potential of these incredible stem cells,” says Julie Joo, Operations Director, who in 2016 became the third employee of Hope Biosciences. “But what I see from the inside is the incredible energy of the people. This is like no other company—everyone here is excited to be here. Everyone knows it is important. Everyone sees the power of this work to change the future of healthcare for everyone.”
During their first five years Hope Biosciences grew from one to 21 employees and moved into an expansive building of their own in Sugar Land, Tx., only a short distance from Houston’s renowned medical center. In 2020 Hope Biosciences Stem Cell Research Foundation was founded, through which Hope Biosciences now executes clinical research and patient care. Even in the thrill of astronomical growth, the company maintains their commitment to caring for every cell, every day, by hand.
“We are the caretakers of your cells,” says manufacturing supervisor Hosu Kim. “Every day it is a privilege to be here, to be trusted. I have seen nearly all of these 130 billion cells grow in the four years that I have been part of Hope Bio, and I never lose the sense of amazement.”
Hope Biosciences, headquartered in Sugar Land, Texas, is a biopharmaceutical company developing adult stem cell therapeutics for a variety of clinical indications. Hope Bio is the only clinical grade adult stem cell banking facility in the nation that banks both adults and newborns.
Hope Biosciences executes clinical research through the Hope Biosciences Stem Cell Research Foundation (HBSCRF). To date, HBSCRF has obtained FDA authorization for 16 clinical studies in 10 disease areas. Clinical trial authorizations encompass COVID-19 prevention and treatment, Alzheimer's disease, and traumatic brain injury (TBI). Expanded access protocol authorizations include amyotrophic lateral sclerosis (ALS), primary lateral sclerosis (PLS), severe osteoarthritis, Parkinson's disease, spinal cord injury, Cerebral Palsy, and chronic musculoskeletal pain. In its first year of operation HBSCRF administered nearly 100 billion cells at zero charge to patients.
Learn more about Hope Biosciences at www.hope.bio/about